Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
The Kirsten rat sarcoma (KRAS) oncogene was considered “undruggable” until the development of sotorasib, a KRASG12C selective inhibitor that shows favorable effects against lung cancers. MRTX1133, a novel KRASG12D inhibitor, has shown promising results in basic research, although its effects against...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-02-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13751 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!